ALACHUA, Fla.--(BUSINESS WIRE)--AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that it has received a $2 million milestone payment from Genzyme Corporation as a result of having successfully transferred AGTC’s proprietary Adeno-Associated Virus (AAV) vector production technology to Genzyme.
